Leronlimab (700mg)

DRUG4 trials

Sponsors

CytoDyn, Inc., Weill Medical College of Cornell University

Conditions

Alzheimer's DiseaseCoronavirus Disease 2019Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease

Phase 2

Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19

CompletedNCT04343651

CytoDyn, Inc.Coronavirus Disease 2019

Start: 2020-04-01End: 2021-09-20Updated: 2023-01-04

Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19

CompletedNCT04347239

CytoDyn, Inc.Coronavirus Disease 2019

Start: 2020-04-16End: 2022-06-15Updated: 2025-10-15

Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With Long COVID-19

CompletedNCT04678830

CytoDyn, Inc.Coronavirus Disease 2019

Start: 2021-03-01End: 2021-07-08Updated: 2024-04-11

Safety Assessment of Leronlimab and Its Effect on Brain Inflammation in Alzheimer's Disease

RecruitingNCT07553338

Weill Medical College of Cornell UniversityAlzheimer's Disease, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease

Start: 2026-04-30End: 2027-11-01Target: 20Updated: 2026-05-22

Related Papers

A Randomized Placebo-Controlled Trial of Leronlimab in Mild-To-Moderate COVID-19.

2024-09-301 citations

Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome

Clinical Infectious Diseases2022-04-1426 citations